search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Prevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.


- candidate number14121
- NTR NumberNTR3760
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR19-dec-2012
- Secondary IDs12.12151 METC
- Public TitlePrevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.
- Scientific TitlePrevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.
- ACRONYMN/A
- hypothesisWe assess the prevalence and seriousness of DDIs among ambulatory cancer patients on anti-cancer treatment.
- Healt Condition(s) or Problem(s) studiedCancer, Chemotherapy, Pharmacokinetic interaction, Risk factors, Drug interactions
- Inclusion criteriaAll ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.
- Exclusion criteria1. The use of experimental trial agents;
2. Age <18 years;
3. The use of anti-cancer drugs for non-malignant diseases.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-feb-2013
- planned closingdate1-feb-2015
- Target number of participants500
- InterventionsMedication review in oncology.
- Primary outcomePrevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.
- Secondary outcomeThe secondary objective is to obtain more insight into possible determinants for the occurrence of these DDIs.
- Timepoints1-2-2012: Start study inclusion;
1-2-2013: End study inclusion;
1-2-2013 till 1-2-2013: Analysing, writing.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES Roelof Leeuwen, van
- CONTACT for SCIENTIFIC QUERIES Roelof Leeuwen, van
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Erasmus Medical Center, Stichting Coolsingel
- PublicationsN/A
- Brief summary Drug-drug interactions in patients using anticancer drugs are common, although not always these are recognized by pharmacists and physicians. These interactions may have serious consequences for the number and severity of side-effects and efficacy of treatment. As side-effects could potentially be lethal, and efficacy could be diminished by such interactions, it is extremely important to visualize drug-drug interactions (DDI) on forehand. With a firm increase in available (and chronically used) oral anticancer agents during recent years, the risk for DDIs has become even more important for clinical practice. Outcomes of this study may help physicians and pharmacists to create awareness of DDIs and should lead to a closer collaboration between them to identify and manage these DDIs.
- Main changes (audit trail)
- RECORD19-dec-2012 - 8-jan-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl